Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Aduhelm, ago, American, anesthesiologist, antiviral, argued, binding, capability, Cathepsin, cell, cellular, certified, clinician, constantly, covalent, cysteine, dismissed, dollar, enzyme, excellent, formula, gradually, imprisonment, inpatient, intranasal, irreversible, lung, Mpro, multicenter, nM, nurse, Rescue, source, viral
Removed:
allocate, team
Filing tables
Filing exhibits
QNCX similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)
In connection with the Quarterly Report of Cortexyme, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 6, 2021 | By: | /s/ Christopher Lowe | |
Christopher Lowe | |||
Chief Operating Officer and Chief Financial Officer | |||
|
|
| (Principal Financial Officer) |